The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy
Open accessAbstract
BACKGROUND: The role of trypanocidal therapy in patients with established Chagas' cardiomyopathy is unproven. METHODS: We conducted a prospective, multicenter, randomized study involving 2854 patients with Chagas' cardiomyopathy who received benznidazole or placebo for up to 80 days and were followed for a mean of 5.4 years. The primary outcome in the time-to-event analysis was the first event of any of the components of the composite outcome of death, resuscitated cardiac arrest, sustained ventricular tachycardia, insertion of a pacemaker or implantable cardioverter-defibrillator, cardiac transplantation, new heart failure, stroke, or other thromboembolic event. RESULTS: The primary outcome occurred in 394 patients (27.5%) in the benznidazole group and in 414 (29.1%) in the placebo group (hazard ratio, 0.93; 95% confidence interval [CI], 0.81 to 1.07; P=0.31). At baseline, a polymerase-chain-reaction (PCR) assay was performed on blood samples obtained from 1896 patients; 60.5% had positive results for Trypanosoma cruzi on PCR. The rates of conversion to negative PCR results (PCR conversion) were 66.2% in the benznidazole group and 33.5% in the placebo group at the end of treatment, 55.4% and 35.3%, respectively, at 2 years, and 46.7% and 33.1%, respectively, at 5 years or more (P<0.001 for all comparisons). The effect of treatment on PCR conversion varied according to geographic region: in Brazil, the odds ratio for PCR conversion was 3.03 (95% CI, 2.12 to 4.34) at 2 years and 1.87 (95% CI, 1.33 to 2.63) at 5 or more years; in Colombia and El Salvador, the odds ratio was 1.33 (95% CI, 0.90 to 1.98) at 2 years and 0.96 (95% CI, 0.63 to 1.45) at 5 or more years; and in Argentina and Bolivia, the odds ratio was 2.63 (95% CI, 1.89 to 3.66) at 2 years and 2.79 (95% CI, 1.99 to 3.92) at 5 or more years (P<0.001 for interaction). However, the rates of PCR conversion did not correspond to effects on clinical outcome (P=0.16 for interaction). CONCLUSIONS: Trypanocidal therapy with benznidazole in patients with established Chagas' cardiomyopathy significantly reduced serum parasite detection but did not significantly reduce cardiac clinical deterioration through 5 years of follow-up. (Funded by the Population Health Research Institute and others; ClinicalTrials.gov number, NCT00123916; Current Controlled Trials number, ISRCTN13967269.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K.-Y. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,764
Rassi, A., Rassi, A., & Marin-Neto, J. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60061-x · Cited by 2,119
Self-citationORGANIZACIÓN PANAMERICANA DE LA SALUD
Mujer, P., Desarrollo, S. Y., Costa, F. E., Rica, Carcedo, A. J. P., Sagot, M., de investigación, A., González, C., & Kilfoil, V. (2003) · Cited by 1,881
Pathogenesis of Chronic Chagas Heart Disease
Marin-Neto, J. A., Cunha-Neto, E., Maciel, B. C., & Simões, M. V. (2007) · Circulation · doi:10.1161/circulationaha.106.624296 · Cited by 849
Self-citationEvaluation and Treatment of Chagas Disease in the United States: A Systematic Review
Bern, C., Montgomery, S. P., Herwaldt, B. L., Rassi, A., Marin-Neto, J. A., Dantas, R. O., Maguire, J. H., Acquatella, H., Morillo, C., Kirchhoff, L. V., et al. (2007) · JAMA · doi:10.1001/jama.298.18.2171 · Cited by 775
Self-citationBern, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1410150 · Cited by 770
Development and Validation of a Risk Score for Predicting Death in Chagas' Heart Disease
Rassi, A., Rassi, A., Little, W. C., Xavier, S. S., Rassi, S. G., Rassi, A. G., Rassi, G. G., Hasslocher-Moreno, A., Sousa, A. S., & Scanavacca, M. I. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053241 · Cited by 646
Self-citationRandomized Trial of Posaconazole and Benznidazole for Chronic Chagas' Disease
Molina, I., Gómez i Prat, J., Salvador, F., Treviño, B., Sulleiro, E., Serre, N., Pou, D., Roure, S., Cabezos, J., Valerio, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313122 · Cited by 604
Viotti, R., Vigliano, C., Lococo, B., Bertocchi, G., Petti, M., Alvarez, M. G., Postan, M., & Armenti, A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00006 · Cited by 598
Garcia, S., Ramos, C. O., Senra, J. F. V., Vilas‐Boas, F., Rodrigues, M. M., de Carvalho, A. C. C., Ribeiro‐dos‐Santos, R., & Soares, M. B. P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1521-1528.2005 · Cited by 291
Cited by
Epidemiology and aetiology of heart failure
Ziaeian, B., & Fonarow, G. C. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.25 · Cited by 1,878
Pérez-Molina, J. A., & Molina, I. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31612-4 · Cited by 1,284
Nunes, M. C. P., Beaton, A., Acquatella, H., Bern, C., Bolger, A. F., Echeverría, L. E., Dutra, W. O., Gascon, J., Morillo, C. A., Oliveira-Filho, J., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000599 · Cited by 583
Self-citation2025 ESC Guidelines for the management of myocarditis and pericarditis
Schulz-Menger, J., Collini, V., Gröschel, J., Adler, Y., Brucato, A., Christian, V., Ferreira, V. M., Gandjbakhch, E., Heidecker, B., Kerneis, M., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf192 · Cited by 434
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness
Khare, S., Nagle, A. S., Biggart, A., Lai, Y. H., Liang, F., Davis, L. C., Barnes, S. W., Mathison, C. J. N., Myburgh, E., Gao, M.-Y., et al. (2016) · Nature · doi:10.1038/nature19339 · Cited by 407
Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda
Rohde, L. E. P., Montera, M. W., Bocchi, E. A., Clausell, N. O., Albuquerque, D. C. D., Rassi, S., Colafranceschi, A. S., Freitas Junior, A. F. D., Ferraz, A. S., Biolo, A., et al. (2018) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20180190 · Cited by 377
Neglected tropical diseases: progress towards addressing the chronic pandemic
Molyneux, D. H., Savioli, L., & Engels, D. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30171-4 · Cited by 376
Experimental and Clinical Treatment of Chagas Disease: A Review
Sales Junior, P. A., Molina, I., Fonseca Murta, S. M., Sánchez-Montalvá, A., Salvador, F., Corrêa-Oliveira, R., & Carneiro, C. M. (2017) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.16-0761 · Cited by 305
Inflammatory Cardiomyopathic Syndromes
Trachtenberg, B. H., & Hare, J. M. (2017) · Circulation Research · doi:10.1161/circresaha.117.310221 · Cited by 289
Chagas Disease in the United States: a Public Health Approach
Bern, C., Messenger, L. A., Whitman, J. D., & Maguire, J. H. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00023-19 · Cited by 282
McAloon, C. J., Boylan, L. M., Hamborg, T., Stallard, N., Osman, F., Lim, P. B., & Hayat, S. A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.026 · Cited by 274
Myocarditis in Humans and in Experimental Animal Models
Błyszczuk, P. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00064 · Cited by 161
Metadata
- Authors
- Morillo, C. A., Marin-Neto, J. A., Avezum, A., Sosa-Estani, S., Rassi, A., Rosas, F., Villena, E., Quiroz, R., Bonilla, R., Britto, C., Guhl, F., Velazquez, E., Bonilla, L., Meeks, B., Rao-Melacini, P., Pogue, J., Mattos, A., Lazdins, J., Rassi, A., Connolly, S. J., & Yusuf, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-10
- Volume
- 373
- Issue
- 14
- Pages
- 1295-1306
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2322471444
- Cited by
- 1,014
- References
- 16
- FWCI
- 77.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.